Additional funding brings total funding commitment to $9.79 million and supports GMP manufacturing and IND-enabling toxicology for a Phase 1 clinical study WALTHAM, Mass., Nov. 18, 2026 /PRNewswire/ — Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing lipid…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

